Bekir Tasdemir1, Zuhat Urakci2, Zeki Dostbil3, Kemal Unal4, F Selcuk Simsek5, Fatma Teke6, Cemil Goya7. 1. Department of Nuclear Medicine, Faculty of Medicine, Dicle University, 21280, Diyarbakir, Turkey. drbkr@hotmail.com. 2. Department of Medical Oncology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey. dr.zurak@hotmail.com. 3. Department of Nuclear Medicine, Faculty of Medicine, Dicle University, 21280, Diyarbakir, Turkey. zekidostbil@yahoo.com. 4. Department of Nuclear Medicine, Faculty of Medicine, İzmir University, Izmir, Turkey. kemalinmektubu@yahoo.com. 5. Department of Nuclear Medicine, Elazig Training and Research Hospital, Elazig, Turkey. fselcuksimsek@gmail.com. 6. Department of Radiation Oncology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey. doktorfatmateke@gmail.com. 7. Department of Radiology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey. cegoya1@yahoo.com.
Abstract
PURPOSE: We aimed to evaluate the effectiveness of the brain region imaging in FDG-PET/CT scanning of patients with suspected or diagnosed lung cancer. MATERIALS AND METHODS: We performed the study retrospectively on the medical charts of 427 patients. We divided the FDG-PET/CT field of view (FOV) into four major imaging regions: brain, head-neck, abdomen and pelvis. Metastatic findings on these regions were checked and determined the potential of these findings to affect the chemotherapy or radiotherapy protocol or surgical management. If metastatic findings had a potential to modify these parameters, we named this situation as "clinical contribution". Considering the number of bed positions of these regions, we calculated the clinical contribution of each region and named as "effective clinical contribution". Then, we calculated the metastatic findings, clinical contribution, and effective clinical contribution ratios. RESULTS: We found different brain metastasis ratios for lung cancer, solitary pulmonary mass (SPM), and solitary pulmonary nodule (SPN) groups (8.7, 2.8 and 0.9 %, respectively). In addition, the clinical contribution and effective clinical contribution ratios in the brain region for these three groups were 6.4, 2.8, 0.0 and 6.4, 2.8, 0.0 %, respectively. The highest metastatic findings (30.6 %) and clinical contribution (9.8 %) ratios were found in the abdomen region of the lung cancer group. However, the highest effective clinical contribution ratio (6.8 %) was found in the brain region within the same group. CONCLUSIONS: The addition of the brain region to the limited whole-body FOV in FDG-PET/CT scanning seems to be effective in the lung cancer and SPM groups, but not in the SPN group.
PURPOSE: We aimed to evaluate the effectiveness of the brain region imaging in FDG-PET/CT scanning of patients with suspected or diagnosed lung cancer. MATERIALS AND METHODS: We performed the study retrospectively on the medical charts of 427 patients. We divided the FDG-PET/CT field of view (FOV) into four major imaging regions: brain, head-neck, abdomen and pelvis. Metastatic findings on these regions were checked and determined the potential of these findings to affect the chemotherapy or radiotherapy protocol or surgical management. If metastatic findings had a potential to modify these parameters, we named this situation as "clinical contribution". Considering the number of bed positions of these regions, we calculated the clinical contribution of each region and named as "effective clinical contribution". Then, we calculated the metastatic findings, clinical contribution, and effective clinical contribution ratios. RESULTS: We found different brain metastasis ratios for lung cancer, solitary pulmonary mass (SPM), and solitary pulmonary nodule (SPN) groups (8.7, 2.8 and 0.9 %, respectively). In addition, the clinical contribution and effective clinical contribution ratios in the brain region for these three groups were 6.4, 2.8, 0.0 and 6.4, 2.8, 0.0 %, respectively. The highest metastatic findings (30.6 %) and clinical contribution (9.8 %) ratios were found in the abdomen region of the lung cancer group. However, the highest effective clinical contribution ratio (6.8 %) was found in the brain region within the same group. CONCLUSIONS: The addition of the brain region to the limited whole-body FOV in FDG-PET/CT scanning seems to be effective in the lung cancer and SPM groups, but not in the SPN group.
Entities:
Keywords:
Brain; Field of view; Lung cancer; Positron emission tomography; Solitary pulmonary mass; Solitary pulmonary nodule
Authors: Dominique Delbeke; R Edward Coleman; Milton J Guiberteau; Manuel L Brown; Henry D Royal; Barry A Siegel; David W Townsend; Lincoln L Berland; J Anthony Parker; Karl Hubner; Michael G Stabin; George Zubal; Marc Kachelriess; Valerie Cronin; Scott Holbrook Journal: J Nucl Med Date: 2006-05 Impact factor: 10.057
Authors: Medhat M Osman; Bassem T Chaar; Razi Muzaffar; Dana Oliver; Hans Joachim Reimers; Bruce Walz; Nghi C Nguyen Journal: AJR Am J Roentgenol Date: 2010-12 Impact factor: 3.959
Authors: Ronald Boellaard; Mike J O'Doherty; Wolfgang A Weber; Felix M Mottaghy; Markus N Lonsdale; Sigrid G Stroobants; Wim J G Oyen; Joerg Kotzerke; Otto S Hoekstra; Jan Pruim; Paul K Marsden; Klaus Tatsch; Corneline J Hoekstra; Eric P Visser; Bertjan Arends; Fred J Verzijlbergen; Josee M Zijlstra; Emile F I Comans; Adriaan A Lammertsma; Anne M Paans; Antoon T Willemsen; Thomas Beyer; Andreas Bockisch; Cornelia Schaefer-Prokop; Dominique Delbeke; Richard P Baum; Arturo Chiti; Bernd J Krause Journal: Eur J Nucl Med Mol Imaging Date: 2010-01 Impact factor: 9.236
Authors: Bekir Tasdemir; Zeki Dostbil; Ali Inal; Kemal Unal; Sule Yildirim; F Selcuk Simsek Journal: Biomed Res Int Date: 2014-06-16 Impact factor: 3.411
Authors: Ho Yun Lee; Kyung Soo Lee; Byung-Tae Kim; Young-Seok Cho; Eun Jeong Lee; Chin A Yi; Myung Jin Chung; Tae Sung Kim; O Jung Kwon; Hojoong Kim Journal: J Korean Med Sci Date: 2009-11-09 Impact factor: 2.153
Authors: Marco Spadafora; Leonardo Pace; Laura Evangelista; Luigi Mansi; Francesco Del Prete; Giorgio Saladini; Paolo Miletto; Stefano Fanti; Silvana Del Vecchio; Luca Guerra; Giovanna Pepe; Giuseppina Peluso; Emanuele Nicolai; Giovanni Storto; Marco Ferdeghini; Alessandro Giordano; Mohsen Farsad; Orazio Schillaci; Cesare Gridelli; Alberto Cuocolo Journal: Eur J Nucl Med Mol Imaging Date: 2018-05-05 Impact factor: 9.236
Authors: Marco Spadafora; Laura Evangelista; Salvatore Fiordoro; Francesco Porcaro; Marilena Sicignano; Luigi Mansi Journal: Curr Radiopharm Date: 2020